Related Experiment Videos
High-dose chemotherapy in soft tissue sarcoma in children
1Department of Paediatric Oncology, The Royal Marsden Hospital NHS Trust/Institute of Cancer Research, Downs Road, Sutton, SM2 5PT, Surrey, UK.
Critical Reviews in Oncology/Hematology
|February 22, 2002
Summary
High-risk soft tissue sarcomas (STS) in children, especially metastatic rhabdomyosarcoma (RMS), have poor outcomes despite intensive treatments. International collaboration is needed to improve survival rates for these challenging pediatric cancers.
Area of Science:
- Pediatric Oncology
- Cancer Biology
- Medical Research
Background:
- Soft tissue sarcomas (STS) are rare but aggressive childhood cancers, with rhabdomyosarcoma (RMS) being the most frequent type.
- While many children achieve cure with standard therapies, those with metastatic disease at diagnosis face a significantly worse prognosis.
- High-risk pediatric STS, particularly metastatic RMS in older children or those with bone/marrow involvement, necessitates advanced treatment strategies.
Purpose of the Study:
- To review the current therapeutic approaches for high-risk pediatric soft tissue sarcomas, focusing on metastatic rhabdomyosarcoma.
- To evaluate the efficacy and challenges of high-dose therapy with stem cell rescue in this patient subgroup.
- To highlight the need for international collaboration to enhance treatment outcomes for children with high-risk STS.
Main Methods:
- Review of existing literature and clinical trials concerning high-dose therapy and stem cell rescue for pediatric STS.
- Analysis of treatment outcomes in children with metastatic rhabdomyosarcoma, considering age and disease involvement.
- Examination of novel therapeutic strategies, including sequential high-dose chemotherapy.
Main Results:
- Conventional chemotherapy and local therapy are effective for most pediatric RMS cases but yield poor results in high-risk metastatic disease.
- High-dose therapy with stem cell rescue has been explored for two decades with limited success in improving outcomes for high-risk STS.
- Sequential high-dose chemotherapy shows feasibility in early treatment phases, but its definitive benefit requires further confirmation; the role of purging remains uncertain.
Conclusions:
- Children with high-risk metastatic soft tissue sarcomas, especially rhabdomyosarcoma, continue to have poor prognoses.
- Current intensive treatment strategies, including high-dose therapy and stem cell rescue, have not significantly improved outcomes.
- Urgent international collaboration is essential to develop and implement more effective therapeutic approaches for improving survival in pediatric high-risk STS.